AspenTech (Aspen Technology, Inc.)

AspenTech (Aspen Technology, Inc.) is an industrial software company specialising in asset optimisation for process manufacturing and asset-intensive industries, founded in 1981. It provides software for Manufacturing Execution Systems (MES), Asset Performance Management (APM), planning and scheduling, performance engineering, digital grid management, and subsurface science.

In 2022, Emerson combined its software businesses (including OSI Inc. and Geological Simulation Software) with AspenTech in a $6 billion transaction, acquiring 55% ownership. In 2025, Emerson acquired the remaining 43% for $7.2 billion, making AspenTech a wholly-owned subsidiary. The combined portfolio serves pharmaceuticals, chemicals, oil & gas, energy, metals & mining, and power generation.

AspenTech has 4,338 employees globally and is headquartered in Bedford, Massachusetts. It operates as a business unit within Emerson's automation portfolio.

AspenTech is a multi-industry software provider serving asset-intensive sectors, with pharmaceuticals one of several verticals. The company offers Manufacturing Execution Systems designed for pharmaceutical manufacturing. It addresses FDA 21 CFR Part 11, EU Annex 11, and cGMP requirements for pharmaceutical operations.

GlaxoSmithKline (GSK) is a named pharmaceutical customer with documented case studies showing batch release time improvements using AspenTech solutions. AspenTech is an ISPE sponsor and partner in Pharma 4.0 initiatives. It serves pharmaceutical manufacturers requiring process optimisation, manufacturing execution, and asset performance management for regulated production environments.

Emerson invested $6 billion for 55% ownership of AspenTech in 2022, combining its software businesses — including OSI Inc. (Digital Grid Management) and Geological Simulation Software — with AspenTech's existing portfolio. In 2025, Emerson acquired the remaining 43% for $7.2 billion, making AspenTech a wholly-owned subsidiary; the two transactions total over $13 billion.

Annual spend was $629 million at the end of Q1 FY2022, a 5.5% year-over-year increase. The acquisitions added digital grid management (OSI) and subsurface science capabilities to AspenTech's product portfolio. AspenTech operates within Emerson's automation solutions portfolio.

AspenTech offers an industrial software portfolio spanning Manufacturing Execution Systems (MES), Asset Performance Management (APM), planning and scheduling, performance engineering, digital grid management, and subsurface science. The MES portfolio includes Production Execution Manager, designed for pharmaceutical manufacturing with FDA 21 CFR Part 11 compliance. Asset Performance Management solutions include Aspen Mtell for predictive maintenance and Aspen ProMV for process monitoring and optimisation.

Following the 2022 Emerson combination, the product portfolio expanded to include OSI's Digital Grid Management software for power and utilities sectors, and Geological Simulation Software for subsurface science applications in oil & gas exploration. The planning and scheduling solutions optimise production planning for process industries. Performance engineering tools support process design and optimisation. AspenTech markets the suite as integrated across the asset lifecycle, from design through operations and maintenance.

AspenTech partners with Körber on integrated solutions for pharmaceutical and life sciences manufacturers. As an Emerson subsidiary, it integrates with Emerson's automation and operational technology systems.

AspenTech is an ISPE (International Society for Pharmaceutical Engineering) sponsor and partner, participating in Pharma 4.0 initiatives for digital transformation in pharmaceutical manufacturing.

AspenTech provides professional services for implementation, validation, and training for its industrial software solutions. With 4,338 employees globally, the company maintains support capabilities across major regions serving asset-intensive industries. As an Emerson subsidiary, AspenTech customers have access to Emerson's global service network.

For pharmaceutical customers, AspenTech offers implementation services addressing FDA 21 CFR Part 11 and EU Annex 11 validation requirements. Its professional services cover system integration, process optimisation, and ongoing technical support for manufacturing execution and asset performance management deployments.

AspenTech has served asset-intensive industries since 1981, more than 40 years. It is an ISPE sponsor with active participation in Pharma 4.0 initiatives, and addresses FDA 21 CFR Part 11, EU Annex 11, and cGMP requirements.

Emerson completed 100% ownership of AspenTech in a 2025 acquisition for $7.2 billion. Named pharmaceutical customer GlaxoSmithKline (GSK) has documented case studies of AspenTech solutions in production environments. AspenTech is part of Emerson's industrial automation portfolio, a Fortune 500 company.

AspenTech has 4,338 employees globally and maintains an active LinkedIn presence.

The 2022 Emerson combination (55% ownership for $6 billion) and 2025 acquisition (remaining 43% for $7.2 billion) generated industry press coverage. AspenTech's website at www.aspentech.com provides product information and resources for industrial software buyers.